BMI1 Inhibition and PD-1 Blockade for HNSCC Relapse Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy methods, such as PD-1 blockade, are ineffective in eliminating cancer stem cells (CSCs) and preventing tumor relapse in head and neck squamous cell carcinoma (HNSCC), as CSCs can evade immune responses and promote an immunosuppressive tumor microenvironment.
Innovation Solution
The combination of administering an agent that blocks PD-1 signaling and an agent that reduces BMI-1 expression or function, specifically using the BMI-1 inhibitor PTC209, to eliminate BMI-1+ CSCs and activate tumor-intrinsic immunity, thereby inhibiting metastatic tumor growth and preventing relapse.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1 blockade is used to treat HNSCC, then immune response is activated, but cancer stem cells can evade immune responses and promote immunosuppressive tumor microenvironment
Solution Approach 1:
The patent segments the therapeutic approach by combining two distinct mechanisms: PD-1 blockade to activate immune response and BMI1 inhibition to eliminate cancer stem cells. This segmentation addresses the limitation of PD-1 blockade alone by targeting both the immune suppression pathway and the CSC-mediated immunosuppressive microenvironment
Solution Approach 2:
The patent merges PD-1 blockade therapy with BMI1 inhibition into a combination therapy regimen. This merging creates a synergistic effect where the immune-activating effect of PD-1 blockade is enhanced by the CSC-eliminating effect of BMI1 inhibition, thereby overcoming the immunosuppressive microenvironment that CSCs create
2Reliability
If PD-1 blockade is used to treat HNSCC, then tumor growth is inhibited, but tumor relapse occurs due to persistence of cancer stem cells
Solution Approach 1:
The patent applies preliminary action by eliminating cancer stem cells through BMI1 inhibition before or concurrent with PD-1 blockade therapy. By removing the reservoir of tumor-initiating cells that cause relapse, the therapy extends the duration of response and prevents tumor recurrence
Solution Approach 2:
The combination of PD-1 blockade and BMI1 inhibition merges tumor growth inhibition with cancer stem cell elimination, thereby extending the duration of therapeutic response and preventing relapse that occurs with PD-1 blockade alone
3Reliability
If cancer stem cells are targeted to improve immunotherapy efficacy, then complete regression of tumors can be achieved, but current methods cannot effectively eliminate CSCs due to their immunosuppressive properties
Solution Approach 1:
The patent converts the harmful immunosuppressive properties of cancer stem cells into a beneficial target. By using BMI1 inhibition to specifically eliminate CSCs, the therapy removes the source of immune suppression and transforms the previously harmful CSC population into a targeted vulnerability that enhances overall immunotherapy efficacy
Solution Approach 2:
The patent merges CSC-targeting therapy with immunotherapy by combining BMI1 inhibition with PD-1 blockade. This combination achieves complete tumor regression by simultaneously eliminating CSCs and activating the immune system, overcoming the limitation of neither approach working alone
Data Source
AI summary
The present disclosure reports that pharmacological or genetic inhibition of Moloney murine leukemia virus insertion site 1 (BMI1) not only helped to eliminate BMI1+ cancer stem cells (CSCs), but can also augment PD1 blockade by strongly induced tumor cell-intrinsic immune responses by recruiting and activating CD8+ T cells. Taken together, the results indicate that in addition to purging CSCs, targeting BMI1 would enable immune checkpoint blockade to inhibit metastatic tumor growth and prevent tumor relapse by activating cell-intrinsic immunity.